31 results about "P2Y12" patented technology

A method is provided for measuring inhibition of platelet reactivity in an individual treated with a drug-eluting stent (DES). First, a blood sample is obtained from an individual treated with a DES and a P2Y12 antagonist. The blood sample is then mixed with particles comprising an attached GPIIb / IIIa receptor ligand, adenosine diphosphate (ADP) and prostaglandin E1 (PGE1). The mixture is incubated under conditions suitable for agglutinating particles, and platelet-mediated agglutination is assessed in the mixture. The absence or reduction of agglutination indicates that the individual treated with a DES has reduced platelet reactivity. Also provided is a kit for measuring inhibition of platelet aggregation by a P2Y12 receptor antagonist that includes a GPIIb / IIIa receptor ligand immobilized on a particle, adenosine diphosphate (ADP), prostaglandin E1 (PGE1), an anticoagulant, and a buffer to maintain the anticoagulated blood in a condition suitable for platelet aggregation.

The invention provides methods and compositions for rapid and reversible inhibition of platelet aggregation in human subjects in need thereof by administering compounds of the formula:alone or in combination with a second agent which can be aspirin or a thrombolytic agent.

The present invention relates to certain novel pyridin compounds of Formula (I) to processes for preparing such compounds, to their utility as P2Y12 inhibitors and as anti-trombotic agents etc, and processes for their preparation, their use as medicaments in cardiovascular diseases as well as pharmaceutical compositions containing them.

The invention relates to 2-phenyl-6-aminocarbonyl-pyrimidine derivatives and their use as P2Y12 receptor antagonists in the treatment and / or prevention and / or treatment of peripheral vascular, of visceral-, hepatic- and renal-vascular, of cardiovascular and of cerebrovascular diseases or conditions associated with platelet aggregation, including thrombosis in humans and other mammals. Formula (I).

The present invention relates to certain novel pyridin compounds of Formula (I) to processes for preparing such compounds, to their utility as P2Y12 inhibitors and as anti-thrombotic agents etc, and processes for their preparation, their use as medicaments in cardiovascular diseases as well as pharmaceutical compositions containing them.

The present invention relates to certain new pyridin analogues of Formula (I) to processes for preparing such compounds, to their utility as P2Y12 inhibitors and as anti-trombotic agents etc, their use as medicaments in cardiovascular diseases as well as pharmaceutical compositions containing them.

Provided is a method of treating or preventing age-related macular degeneration (AMD) in a patient subject to, or symptomatic of the disease, wherein the method comprises restoring normal lysosomal pH (pHL), or acidifying an abnormally elevated pHL, thus decreasing or preventing a damaging accumulation of lipofuscin or waste products in the retinal pigment epithelium (RPE) cells of the eye of the patient. Further, this method is achieved by modulating the action of the P2X7 and / or P2Y12 receptors of the RPE cells, specifically decreasing the acidity (pHL) of the RPE lysosomes by administering selected receptor antagonists affecting the action of the P2X7 and / or P2Y12 receptors of the RPE. Methods for selecting and quantifying the effectiveness of drugs to restore pHL and determine outer segment clearance rates is also provided using a high through-put screening protocol.

The invention provides an application of GFA (Guanfu base A) in preparation of a drug for neuropathic pain. Experiments prove that GFA can reduce expression of a P2Y12 receptor of DRG (dorsal root ganglion) SGCs (satellite glial cells), inhibit transmission of nociceptive information mediated by a P2Y12 receptor and inflammatory factors in DRG and reduce pain behavior of rats suffering from neuropathic pain, and can be applied to preparation of the drug for neuropathic pain and diseases related to nerve injury.

The invention relates to an application of a receptor p2y12 of ADP (adenosine diphosphate) in angiogenesis. Concretely, the receptor p2y12 of ADP is specifically expressed in vascular endothelial cells, and a specific inhibitor of p2y12 is used for inhibiting p2y12 expression and preventing blood vessels among somites from generating growth defects; the ligand ADP of p2y12 is also involved in angiogenesis, and a high-selectivity antagonist is utilized to block ADP to activate p2y12 to have an exception which is the same as the above exception; an ADP-p2y12 signal is involved in the angiogenesis process in modes of migrating and proliferating tip cells, namely regulating tip cell behaviors; otherwise, p2y12 overexpression can promote the obtaining of tip cell, namely the number of endothelial cells with excessive migration and endothelial cells involved in angiogenesis among somites is obviously increased; in addition, the ADP-p2y12 signal inhibits a notch pathway so as to regulate angiogenesis in vivo. The application of the receptor p2y12 of ADPin angiogenesis provides a new target for related diseases of intervention in angiogenesis.

The invention discloses a blood purification modified membrane and a preparation method thereof. The preparation method comprises the following steps: (1) preparation of citric acid-coupled chitosan; (2) preparation of CA‑CTS-loaded ticagrelor microspheres; and (3) preparation of a blood purification modified membrane. The invention utilizes the hydrophilicity and anticoagulant properties of citric acid to prepare a blood purification modified membrane by putting ticagrelor into the microsphere particles, so that the modified membrane can directly act on the P2Y12 receptor, thereby directly inhibiting Platelet activity, in order to achieve the effect of slow-release anti-inflammatory and anti-thrombotic, and the release is stable. The blood purification modified membrane of the present application has low cost, good anti-inflammatory and antithrombotic properties, can release ticagrelor into the blood stably and slowly, and has good blood compatibility.